MedTrace Logo

Safety Study of PTP-001 for Treating Knee Osteoarthritis

NCT04632966 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-12-22

No results posted yet for this study

Summary

Evaluation of safety, tolerability, and efficacy of a single intra-articular (IA) injection of PTP-001, an allogeneic placental tissue particulate, in individuals with knee osteoarthritis (OA).

Conditions

Interventions

BIOLOGICAL

Biological: PTP-001

allogeneic placental tissue particulate

Sponsors & Collaborators

  • Bioventus LLC

    lead INDUSTRY

Principal Investigators

  • Annunziato Amendola, MD · James R. Urbaniak, MD, Duke Sports Science Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-26
Primary Completion
2022-09-30
Completion
2022-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04632966 on ClinicalTrials.gov